Alpha4beta2 Nicotinic Receptor Ligands for CNS Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nicotinic acetylcholine receptor compounds are insufficient for effectively modulating α4β2 nicotinic receptors, which are implicated in various central nervous system disorders, including cognitive impairments, pain, and addiction, highlighting a need for more potent and specific therapeutic agents.
Innovation Solution
Development of novel α4β2 neuronal nicotinic acetylcholine receptor ligand compounds of the formula (I) and their stereoisomers, along with their pharmaceutically acceptable salts, which demonstrate high affinity for nicotinic acetylcholine receptors and are used in pharmaceutical compositions for treating disorders such as anxiety, Alzheimer's disease, and addiction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current nicotinic acetylcholine receptor compounds are used, then basic receptor modulation is achieved, but insufficient efficacy and specificity for α4β2 nicotinic receptors is observed
Solution Approach 1:
The patent applies local quality by introducing specific substituent groups (R1-R6) at defined positions on the bicyclic core structure, creating localized chemical modifications that enhance affinity for α4β2 receptors. The use of specific heterocyclic rings (pyridine, pyrimidine, triazine) at particular positions provides targeted interactions with receptor binding sites, improving both efficacy and specificity simultaneously.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters including substituent types (halogens, alkyl groups, heterocycles), substitution patterns, and molecular configuration. These parameter modifications optimize the compound's pharmacological profile to achieve high affinity and specificity for α4β2 nicotinic receptors while maintaining desired therapeutic efficacy.
2Reliability
If novel compounds of formula (I) are developed, then high affinity and efficacy for α4β2 receptors is achieved, but increased structural complexity is introduced
Solution Approach 1:
The patent applies segmentation by dividing the molecule into a core bicyclic structure and separate substituent groups (R1-R6) that can be independently optimized. This modular approach allows systematic exploration of structure-activity relationships while maintaining a manageable core framework, balancing affinity enhancement with structural complexity.
Solution Approach 2:
The patent employs universality by designing a versatile bicyclic core structure that can accommodate multiple types of substituents (heterocyclic, aromatic, aliphatic groups). This universal scaffold provides a platform for generating multiple analogs with optimized properties, achieving high affinity through diverse substituent combinations rather than complexing the core structure itself.
Data Source
AI summary
The present invention relates to novel a4ß2 neuronal nicotinic acetylcholine receptor ligand compounds of the formula (I), and their derivatives, stereoisomers, pharmaceutically acceptable salts and compositions containing them. The present invention relates to novel a4ß2 neuronal nicotinic acetylcholine receptor ligand compounds of the formula (I), and their derivatives, stereoisomers, pharmaceutically acceptable salts and compositions containing them.